News

News and Press Releases
About the CF Foundation | CFTR Modulators CF Therapy Kalydeco Receives Approval in the European Union

The European Commission has approved the use of the CF therapy Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.

| 1 min read
About the CF Foundation | CFTR Modulators Kalydeco Receives Recommendation for Approval in the European Union

The European Medicines Agency (EMA) announced today that it has recommended the approval of the CF drug Kalydeco™ for people with the G551D mutation ages 6 and older in the European Union.

| 2 min read
About the CF Foundation | Public Policy EXPERRT Act Benefiting Cystic Fibrosis and Other Rare Diseases Included in FDA Legislation

The U.S. House of Representatives and the Senate have both incorporated the Expanding and Promoting Expertise in Review of Rare Treatments Act (EXPERRT Act), championed by the CF Foundation, as part of a legislative package to reauthorize the U.S. Food and Drug Administration's (FDA) system for evaluating new prescription drugs and devices.

| 1 min read
About the CF Foundation | Public Policy | Advocacy CF Foundation Advocates March on the Hill to Attract Support from Members of Congress

On March 8, more than 40 Cystic Fibrosis Foundation volunteers from across the nation came together on Capitol Hill to speak out on behalf of their friends and family members with cystic fibrosis.

| 2 min read
About the CF Foundation | Drug Pipeline | Medications FDA Approves Ultresa — Pancreatic Enzyme Therapy for People with CF

The U.S. Food and Drug Administration (FDA) announced that it has approved Ultresa™ delayed-release capsules, a pancreatic enzyme replacement therapy. Ultresa (pancrelipase) is manufactured by Aptalis Pharma.

| 1 min read